CLDXCelldex Therapeutics, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$730,000-70.8% YoY

Gross Profit

$730,000100.0% margin

Operating Income

-$64M-8747.5% margin

Net Income

-$57M-7753.4% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$45M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$692M

Total Liabilities

$37M

Stockholders' Equity

$655M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$730,000	$2M	-70.8%
Gross Profit	$730,000	$2M	-57.1%
Operating Income	-$64M	-$46M	-37.9%
Net Income	-$57M	-$36M	-57.9%

Revenue Segments

Grant

$723,00099%

Service

$7,0001%

CLDX Q2 2025 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena